Your session is about to expire
← Back to Search
AMAB + continuous estrogen for Cardiovascular Disease
N/A
Recruiting
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0.5 hours
Awards & highlights
Summary
The goal of this study is to learn how long-term use of estrogen affects blood vessels in healthy adults who were assigned male at birth. Participants will: give one blood draw of 5 mL have a camera placed under the tongue to take pictures of blood vessels have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.
Eligible Conditions
- Cardiovascular Disease
- Estrogen
- Microvasculature
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0.5 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0.5 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Perfused Vessel Density
Change in blood vessel dilation
Trial Design
2Treatment groups
Experimental Treatment
Group I: AMAB - continuous estrogenExperimental Treatment3 Interventions
Identify as assigned male at birth (AMAB) who have not had continuous estrogen treatment for a minimum of 1 year.
Group II: AMAB + continuous estrogenExperimental Treatment3 Interventions
Identify as assigned male at birth (AMAB) who have had continuous estrogen treatment for a minimum of 1 year.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetylcholine
2013
Completed Phase 2
~220
Sodium Nitroprusside
2018
Completed Phase 1
~240
Find a Location
Who is running the clinical trial?
Medical College of WisconsinLead Sponsor
614 Previous Clinical Trials
1,162,859 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger